Applied Clinical Trials

Go behind the pages of Applied Clinical Trials

Subscribe Listen in podnod RSS feed Show website

20 episodes
Updated Yesterday

Episodes20

Newest first

Yesterday · 1 min
ACT Brief: Real-Time Monitoring Through Quick Wins, Consumer Wearable Validation Requirements, and Replimune RP1 Efficacy Data Advancement
In today's ACT Brief, we examine how a gradual, win-driven strategy scales real-time monitoring adoption, why consumer wearables need rigorous fit-for-purpose validation, and an FDA committee's favorable vote on Replimune's oncolytic virus combination therapy.
Friday · 1 min
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
In today's ACT Brief, we examine why real-time monitoring scales only through coordinated ecosystem efforts, how organizational failures not models explain weak AI results, and FDA's advisory panel peptide compounding decision.
Thursday · 1 min
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
In today's ACT Brief, we examine how sustainability is shifting from compliance to a procurement driver, what infrastructure gaps remain in FDA's real-time pilot model, and regulatory guidance targeting unnecessarily restrictive cancer trial criteria.
Wednesday · 20 min
Beyond Compliance: YPrime's Paulo Limgenco on Moving ESG From Reporting to Real Business Value
In this pilot episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Paulo Limgenco, VP of Business Operations and ESG Strategy Lead at YPrime, about how sustainability is shifting from a compliance checkbox to a factor that shapes vendor selection, client trust, and long-term business value.
Wednesday · 1 min
ACT Brief: Data Pipeline Standardization for Real-Time Analysis, Sponsor Accountability Beyond Contracts, and Autoimmune Pipeline Expansion
In today's ACT Brief, we examine how data standardization must precede real-time monitoring deployment, why contracts cannot transfer sponsor oversight responsibility, and a strategic acquisition broadening immunology development.
July 28 · 1 min
ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism
In today's ACT Brief, we examine the data collection-to-analysis gap undermining continuous trial monitoring, why AI agents require foundational workflow infrastructure, and FDA approval of a novel ADHD treatment.
July 27 · 1 min
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
In today's ACT Brief, we examine how inspection readiness must accumulate rather than assemble, why AI initiatives stall without disciplined governance, and what US clinical trials need beyond isolated initiatives.
July 24 · 1 min
ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition
In today's ACT Brief, we examine why execution failures originate upstream despite surfacing downstream, how European health data frameworks transform CRO roles, and why US trial competitiveness varies by development phase.
July 23 · 1 min
ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism
In today's ACT Brief, we examine where sponsor capability gaps accumulate in protocol execution, how partnerships are embedding trials in community settings, and whether Project Trialblazer can compete with faster international pathways.
July 22 · 1 min
ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration
In today's ACT Brief, we examine how early assumptions govern development outcomes, why single pivotal trials require portfolio recruitment with integrated technology, and how risk frameworks must embed quality into design from the start.
July 21 · 1 min
ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy
In today's ACT Brief, we examine how outsourcing transfers accountability in sponsor organizations, why biomarker strategy requires understanding tumor biology beyond single targets, and FDA clearance for a novel sciatica treatment.
July 20 · 1 min
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
In today's ACT Brief, we examine how programmatic recruitment requires portfolio funding and behavioral readiness integration, why clinical R&D modernization stalls without systems-level thinking, and FDA's traditional approval of a kidney function-preserving therapy.
July 17 · 1 min
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
In today's ACT Brief, we examine how local-first approaches can redesign clinical trial communication, quantitative evidence on risk-based quality management returns, and FDA approval of an oral cholesterol-lowering therapy.
July 16 · 1 min
ACT Brief: CRO Partnership in Program Recruitment, Psychedelic Trial Design Guidance, and Breast Cancer Pathway Inhibitor
In today's ACT Brief, we examine CRO success through program-level partnership, FDA guidance addressing psychedelic trial design challenges, and approval of a comprehensive cancer pathway inhibitor.
July 15 · 1 min
ACT Brief: Organizational Barriers to Programmatic Recruitment, Scaling Selective Safety Data Collection, and Subcutaneous Alzheimer's Treatment
In today's ACT Brief, we examine how organizational silos block programmatic recruitment strategies, why regulatory collaboration on selective safety data enables scalability, and FDA approval of an at-home Alzheimer's therapy option.
July 14 · 1 min
ACT Brief: Portfolio-Level Recruitment Strategy, Real-Time Burden Sampling, and Platinum-Free Bladder Cancer Therapy
In today's ACT Brief, we examine how sponsors can shift to portfolio-level recruitment strategies, why real-time burden sampling captures operational friction before it becomes risk, and FDA approval of a platinum-free bladder cancer combination.
July 13 · 1 min
ACT Brief: FDA CRL Transparency Pause, Protocol-Centric Recruitment Model Shift, and Medical Affairs Integration in Development
In today's ACT Brief, we examine the FDA's paused real-time complete response letter release policy, why programmatic patient engagement is replacing protocol-centric recruitment, and medical affairs' emerging role in bringing patient perspectives into clinical development.
July 10 · 1 min
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
In today's ACT Brief, we examine how FDA's single pivotal trial shift raises recruitment and retention stakes, why FSP should be viewed as a configurable continuum rather than binary choice, and a new pegfilgrastim biosimilar completing a major G-CSF portfolio.
July 9 · 2 min
ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation
In today's ACT Brief, we examine AI-enabled systems medicine connecting fragmented clinical data, how behavioral readiness and trust drive enrollment more than eligibility criteria, and scaling concentrated AI strategy across a global pharmaceutical enterprise.
July 8 · 1 min
ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots
In today's ACT Brief, we examine how selective safety data collection could ease operational burden and address investigator shortages, why site-specific technology limits AI adoption, and how regulatory pressure and patent cliffs are reshaping R&D investment strategy.